|

Prednisolone Clinical Trials

18 actively recruiting trials across 6 locations

▲ +2 trials since June 2026

Also known as: (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, 15 mg/mL oral solution National Drug Code: 0121-0885-08, Adnisolone, Aprednislon +54 more

Pipeline

Phase 2: 6Phase 3: 8Phase 1/2: 2Phase 2/3: 2

Top Sponsors

  • National Cancer Institute (NCI)3
  • Merck Sharp & Dohme LLC3
  • University of Birmingham1
  • University Hospital, Lille1
  • University Hospital Muenster1

Indications

Other8 trials

A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
Phase 2
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
Phase 3
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Phase 3
PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis
Phase 3
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Phase 3
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Phase 1/2
The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy
Phase 2/3
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Phase 3

Birmingham, Alabama4 trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 2
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Children's Hospital of Alabama

Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Hospital of Alabama

Phase 3
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital of Alabama

Phase 2

Mobile, Alabama2 trials

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Infirmary Cancer Care ( Site 0157)

Phase 2
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

USA Mitchell Cancer Institute ( Site 0173)

Phase 3

Huntsville, Alabama1 trial

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Clearview Cancer Institute

Phase 2

Tucson, Arizona1 trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

ACRC/Arizona Clinical Research Center, Inc

Phase 1/2

Los Angeles, California1 trial

TReatment for ImmUne Mediated PathopHysiology

Children's Hospital Los Angeles

Phase 2

Nashville, Tennessee1 trial

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

SCRI Oncology Partners ( Site 7000)

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.